A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Clinical trial NCT04414475 · RECRUITING
Trial details
- NCT number
- NCT04414475
- Sponsor
- Karyopharm Therapeutics Inc
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-01
- Primary completion
- 2028-01-01
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.